In vivo effect of a dominant negative Kv4.2 loss-of-function mutation eliminating Ito,f on atrial refractoriness and atrial fibrillation in mice

Circulation Journal

Volumn 73, Issue 3, 2009, Pages 461-467

  Odening, Katja E ^a   Nerbonne, Jeanne M ^b   Bode, Christoph ^a   Zehender, Manfred ^a   Brunner, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Atrial refractoriness; In vivo electrophysiological study; Ito,f loss of function mutation; Kv4DN transgenic mice

Indexed keywords

ANTIARRHYTHMIC AGENT; CARBACHOL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV4.2; POTASSIUM ION; SHAL POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOMINANT GENE; FEMALE; GENE MUTATION; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; IN VIVO STUDY; KV4DN GENE; MALE; MOUSE; MUSCLE ACTION POTENTIAL; NONHUMAN; POTASSIUM TRANSPORT;

ACTION POTENTIALS; ANIMALS; ATRIAL FIBRILLATION; CARBACHOL; CARDIOTONIC AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART CONDUCTION SYSTEM; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SEX FACTORS; SHAL POTASSIUM CHANNELS;

EID: 62649112042     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0840     Document Type: Article

References (40)

1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fbrillation: The Framingham Heart Study. Circulation 2004; 110: 1042-1046.
2. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fbrillation (Review). Cardiovasc Res 2002; 54: 230-246.
3. Wang Z, Page P, Nattel S. Mechanism of fecainide's antiarrhythmic action in experimental atrial fbrillation. Circ Res 1992; 71: 271-287.
4. Kirchhof P, Engelen M, Franz MR, Ribbing M, Wasmer K, Breithardt G, et al. Electrophysiological effects of fecainide and sotalol in the human atrium during persistent atrial fbrillation. Basic Res Cardiol 2005; 100: 112-121.
5. Knobloch K, Brendel J, Rosenstein B, Bleich M, Busch AE, Wirth KJ. Atrial-selective antiarrhythmic actions of novel Ikur vs Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs. Med Sci Monit 2004; 10: BR221-BR228.
6. Chen YH, Xu SJ, Bendahhou S, Wang XL, Xu XY, Jin HW, et al. KCNQ1 gain-of-function mutation in familial atrial fbrillation. Science 2003; 10: 251-254.
7. Xia M, Jin Q, Bendahhou S, He Y, Larroque MM, Chen Y, et al. A Kir2.1 gain-of-function mutation underlies familial atrial fbrillation. Biochem Biophys Res Commun 2005; 332: 1012-1019.
8. Yang Y, Xia M, Jin Q, Bendahhou S, Shi J, Chen Y, et al. Identifcation of a KCNE2 gain-of-function mutation in patients with familial atrial fbrillation. Am J Hum Genet 2004; 75: 899-905.
9. Li J, McLerie M, Lopatin AN. Transgenic upregulation of IK1 in the mouse heart leads to multiple abnormalities of cardiac excitability. Am J Physiol Heart Circ Physiol 2004; 287: H2790-H2802.
10. Verheule S, Sato T, Everett T, Engle SK, Otten D, Rubart-von der Lohe M, et al. Increased vulnerability to atrial fbrillation in transgenic mice with selective atrial fbrosis caused by overexpression of TGF-beta1. Circ Res 2004; 11: 1458-1465.
11. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, et al. Atrial contractile dysfunction, fbrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specifc overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 2005; 289: H1456-H1467.
12. Hagendorff A, Schumacher B, Kirchhoff S, Luederitz B, Willecke K. Conduction disturbances and increased atrial vulnerability in connexin40-defcient mice analyzed by transesophageal stimulation. Circulation 1999; 99: 1508-1515.
13. Wakimoto H, Maguire CT, Kovoor P, Hammer PE, Gehrmann J, Triedman JK, et al. Induction of atrial tachycardia and fbrillation in the mouse heart. Cardiovasc Res 2001; 50: 463-473.
14. Kovoor P, Wickman K, Maguire CT, Pu W, Gehrmann J, Berul CI, et al. Evaluation of the role of I(KACh) in atrial fbrillation using a mouse knockout model. J Am Coll Cardiol 2001; 37: 2136-2143.
15. Royer A, Demolombe S, El Harchi A, Le Quang K, Piron J, Toumaniantz G, et al. Expression of human ERG K+ channels in the mouse heart exerts anti-arrhythmic activity. Cardiovasc Res 2005; 65: 128-137.
16. Nygren A, Lomax A, Giles W. Heterogeneity of action potential durations in isolated mouse left and right atria recorded using voltage-sensitive dye mapping. Am J Physiol Heart Circ Physiol 2004; 287: H2634-H2643.
17. Xu H, Li H, Nerbonne JM. Elimination of the transient outward current and action potential prolongation in mouse atrial myocytes expressing a dominant negative Kv4 a-subunit. J Physiol 1999; 519: 11-21.
18. Brunner M, Guo W, Mitchell GF, Buckett PD, Nerbonne JM, Koren G. Characterization of mice with a combined suppression of ITo (Kv4DN) and IK,slow (Kv1DN). Am J Physiol Heart Circ Physiol 2001; 281: H1201-H1209.
19. Barry DM, Xu H, Schuessler RB, Nerbonne JM. Functional knockout of the transient outward current, long-QT syndrome, and cardiac remodeling in mice expressing a dominant-negative Kv4 a subunit. Circ Res 1998; 83: 560-567.
20. Berul CI, Aronovitz MJ, Wang PJ, Mendelsohn ME. In vivo cardiac electrophysiology studies in the mouse. Circulation 1996; 94: 2641-2648.
21. Brunner M, Kodirov SA, Mitchell GF, Buckett PD, Shibata K, Folco EJ, et al. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am J Physiol Heart Circ Physiol 2003; 285: H194-H203.
22. Fukaya H, Niwano S, Satoh D, Masaki Y, Niwano H, Kojima J, et al. Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model. Circ J 2008; 72: 318-326.
23. Nattel S. Atrial electrophysiological remodeling caused by rapid atrial activation: Underlying mechanisms and clinical relevance to atrial fbrillation (Review). Cardiovasc Res 1999; 42: 298-308.
24. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fbrillation begets atrial fbrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
25. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fbrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 2005; 16: 394-396.
26. Okishige K, Uehara H, Miyagi N, Nakamura K, Azegami K, Wakimoto H, et al. Clinical study of the acute effects of intravenous nifekalant on the defbrillation threshold in patients with persistent and paroxysmal atrial fbrillation. Circ J 2008; 72: 76-80.
27. Slavik RS, Tisdale JE, Borzak S. Pharmacologic conversion of atrial fbrillation: A systematic review of available evidence . Prog Cardiovasc Dis 2001; 44: 121-152.
28. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fbrillation. Cochrane Database Syst Rev 2007; 17: CD005049.
29. Sarmast F, Kolli A, Zaitsev A, Parisian K, Dhamoon AS, Guha PK, et al. Cholinergic atrial fbrillation: I(K,ACh) gradients determine unequal K,Ach left/right atrial frequencies and rotor dynamics. Cardiovasc Res 2003; 59: 863-873.
30. Schrickel JW, Bielik H, Yang A, Schimpf R, Shlevkov N, Burkhardt D, et al. Induction of atrial fbrillation in mice by rapid transesopha-geal atrial pacing. Basic Res Cardiol 2002; 97: 452-460.
31. Zhang C, Yasuno S, Kuwahara K, Zankov DP, Kobori A, Makiyama T, et al. Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy. Circ J 2006; 70: 335-341.
32. Hayashi H, Wang C, Miyauchi Y, Omichi C, Pak HN, Zhou S, et al. Aging-related increase to inducible atrial fbrillation in the rat model. J Cardiovasc Electrophysiol 2002; 13: 801-808.
33. Huang C, Ding W, Li L, Zhao D. Differences in the aging-associated trends of the monophasic action potential duration and effective refractory period of the right and left atria of the rat. Circ J 2006; 70: 352-357.
34. Marionneau C, Couette B, Liu J, Li H, Mangoni ME, Nargeot J, et al. Specifc pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. J Physiol 2005; 562: 223-234.
35. Xu H, Guo W, Nerbonne JM. Four kinetically distinct depolarization activated outward K currents in adult mouse ventricular myocytes. J Gen Physiol 1999; 113: 661-677.
36. Zhou J, Kodirov S, Murata M, Buckett PD, Nerbonne JM, Koren G. Regional upregulation of Kv2.1-encoded current, IKs,slow2 in Kv1DN mice is abolished by cross-breeding with Kv2DN mice. Am J Physiol Heart Circ Physiol 2003; 284: H491-H500.
37. Schmeling WT, Warltier DC, McDonald DJ, Madsen KE, Atlee JL, Kampine JP. Prolongation of the QT interval by enfurane, isofurane, and halothane in humans. Anesth Analg 1991; 72: 137-144.
38. Saarnivaara L, Hiller A, Oikkonen M. QT interval, heart rate and arterial pressures using propofol, thiopentone or methohexitone for induction of anaesthesia in children. Acta Anaesthesiol Scand 1993; 37: 419-423.
39. Odening KE, Hyder O, Chaves L, Schofeld L, Brunner M, Kirk M, et al. Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specifc differential effects on cardiac repolarization. Am J Physiol Heart Circ Physiol 2008; 295: H2264-H2272.
40. Durieux ME. Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg 1995; 81: 57-62.